Get the Stockscreener App
0.468
41.86%
0.1381
Vivosim Labs Inc stock is traded at $0.468, with a volume of 96.12M.
It is up +41.86% in the last 24 hours and down -48.22% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$0.3299
Open:
$0.324
24h Volume:
96.12M
Relative Volume:
30.63
Market Cap:
$1.64M
Revenue:
$142.00K
Net Income/Loss:
$-1.23M
P/E Ratio:
1.0049
EPS:
0.4657
Net Cash Flow:
$-10.62M
1W Performance:
+35.81%
1M Performance:
-48.22%
6M Performance:
-79.47%
1Y Performance:
-73.21%
1-Day Range:
$0.3086
$0.5833
1-Week Range:
$0.308
$0.5833
52-Week Range:
$0.308
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.468 | 1.36M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
VivoSim Labs, Inc. Revenue Breakdown – NASDAQ:VIVS - TradingView
VIVS|VivoSim Labs Ord Shs|Price:0.413|Chg%:-0.037 - TradingKey
VivoSim Labs Addresses Nasdaq Listing Compliance Concerns - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VIVS|VivoSim Labs Ord Shs|Price:0.419|Chg%:-0.031 - TradingKey
VivoSim Labs, Inc. (VIVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - Yahoo Finance UK
VivoSim Labs (VIVS) Holds Steady Near Support at $0.45 Amid Low VolatilityFactor ETF Flow - dars.gov.et
VIVS Expands into China with First Commercial Sales - GuruFocus
VivoSim secures first commercial sales in China market By Investing.com - Investing.com South Africa
VivoSim secures first commercial sales in China market - Investing.com UK
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services - GlobeNewswire
VivoSim Labs Raises $4 Million in At-the-Market Private Placement to Advance 3D Human Tissue Models for Drug Safety Testing 1 – Minichart - Minichart
VivoSim Labs Announces $4 Million Private Placement Financing - TipRanks
VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants - TradingView
VivoSim prices $0.85 warrants in $4 million private placement - Bitget
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor - Sahm
Why is VivoSim Labs stock falling Thursday? - MSN
VivoSim Labs raises $4M in private placement - Investing.com India
VivoSim Labs prices USD 4 million private placement at USD 0.85 per share - Bitget
VivoSim Labs raises $4M in private placement By Investing.com - Investing.com Nigeria
In today's session, these stocks are experiencing unusual volume. - ChartMill
Why Is VivoSim Labs Stock Falling Thursday? - Benzinga
This stock ticker got caught practicing. It was working last... - Moomoo
VivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant Amendment - Quiver Quantitative
VivoSim Announces Pricing of $4.0 Million Private Placement - GlobeNewswire
Why Vivosim Labs Shares Are Rocketing on Wednesday? - Sahm
VivoSim Labs, Inc. announced that it expects to receive $4.000001 million in funding - marketscreener.com
VivoSim Labs (NASDAQ:VIVS) hits $5M milestone; company says 500% revenue jump comes off $131K base - TechStock²
Why is VivoSim Labs stock sliding today? By Investing.com - Investing.com Canada
VivoSim receives $5M milestone payment from Eli Lilly By Investing.com - Investing.com South Africa
VivoSim Labs (VIVS) Forecasts 500% Revenue Growth, Secures $5M M - GuruFocus
Eli Lilly Milestone and Triple-Digit Growth Outlook Put This Microcap in Focus - The Globe and Mail
VivoSim receives $5 million Eli Lilly milestone - grafa.com
VivoSim Labs Rallies on Heavy Volume After Late Annual Report Filing - Quiver Quantitative
VivoSim Gains on Revenue Word - Baystreet.ca
VivoSim Labs stock falls 29% on $4M private placement - scanx.trade
VIVS Stock Whipsaws As Traders Target Volatile Moves - StocksToTrade
VivoSim Receives $5 Million Eli Lilly Milestone Payment, Issues Fiscal 2027 Revenue Growth Outlook - Moomoo
Vivosim Labs, Inc. Provides Revenue Guidance for Fiscal Year 2027 - marketscreener.com
VIVS Predicts Over 500% Revenue Growth by Fiscal Year 2027 - GuruFocus
VIVS Stock Whipsaws As Traders Zero In On Cash Runway - timothysykes.com
VivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth Guidance - Quiver Quantitative
VivoSim Labs Sees FY27 Rev Growing Significantly >VIVS - Moomoo
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 - Toronto Star
VivoSim: Fiscal Q4 Earnings Snapshot - marketscreener.com
VivoSim Labs, INC. FY 2026: Revenue $0.13M, Net loss $13.84M, EPS $(5.35) — 10-K Summary - TradingView
VivoSim Labs, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 - marketscreener.com
VivoSim Labs, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
VivoSim Labs (VIVS) Tumbles 7.55%: Key Support Levels in FocusCall Dominated - dars.gov.et
VivoSim Labs Faces 7.5% Decline as Stock Tests Key Support at $0.93McClellan Summation - dars.gov.et
Vivosim Labs Inc Stock (VIVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):